Johnson & Johnson (JNJ) closed the latest trading day at $144.62, indicating a +0.89% change from the previous session's end. The stock's change was more than the S&P 500's daily loss of 0.43%.

BofA analyst Tim Anderson lowered the firm’s price target on Johnson & Johnson to $160 from $166 and keeps a Neutral rating on the shares.

Now, scientists at Johnson & Johnson think they have a drug combination that can take survival for these patients even further. The combination is a duo of two drugs from J&J and Janssen ...

In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...